Skip to content

Author

M. di Maio

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whe...

M. Germani, A. Taravella, D. Rossini et al. · 0 citations

with therapeutic

All cases of combined carcinoid and non-small cell lung cancer are summarized, focusing on clinical, morphological, and biological features, suggesting the need to recognize and include this entity as a separate class, in particular for its distinct therapeutic implications.

N. Rossi, P. Parente, Luisella Righi et al. · 0 citations
Review Open access Sep 2026

Quality of life in first-line trials for endometrial cancer: A systematic review.

OBJECTIVE As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC. METHODS Data from phase II...

V. Tuninetti, A. Farolfi, Simona Butticè et al. · 0 citations
Review Open access Sep 2026

Global management of drug–drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist

Abstract Background Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug–drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practi...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · 0 citations
Review Open access Aug 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.